Drugs.com - Clinical Trials

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

NEW YORK--(BUSINESS WIRE) April 26, 2025 -- Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC)...

Apr 30, 2025 - 23:43
 0
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK--(BUSINESS WIRE) April 26, 2025 -- Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC)...
Read More

Tags:

Previous Article

Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of M...

Next Article

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Highest Complete Response R...

Related Posts

AI Screening for Opioid Use Disorder Associated with Fewer Hospital Readmissions

AI Screening for Opioid Use Disorder Associated with Fe...

Apr 26, 2025  0

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant Announces Positive Results for Batoclimab My...

Apr 26, 2025  0

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Granted Three U.S. FDA Fast Track Designations...

Apr 26, 2025  0